LMC Manna Research的首席医疗官罗尼-阿伦森（Ronnie Aronson）博士分享了我们的最新出版物，该出版物展示了我们在过去十年中与利血那肽和利喜兰（利血那肽和兰图斯复方制剂）这两种药物开展的合作。该出版物是我们与利血那肽和利喜兰（利血那肽和兰图斯复方制剂）合作的成果。
This publication is a post-hoc analysis of the data accumulated in the two phase 3 LixiLan trials to explore whether patients benefitted from improved glycemic variability in using the combination LixiLan product. See our abstract below for further information on this latest publication.
Abstract
Maintaining optimal glycaemic control reduces the risk of micro- and macrovascular complications in patients with type 2 diabetes. Typically, glycaemic control is based on glycated haemoglobin (HbA1c) as a measure of mean glucose concentration; however, this marker does not accurately reflect glycaemic variability (GV), which is characterized by the amplitude, frequency and duration of hypo- and hyperglycaemic fluctuations. In the present study, we analysed data from the LixiLan-O trial, which compared iGlarLixi, a titratable fixed-ratio combination of the glucagon-like peptide-1 receptor agonist lixisenatide (Lixi) and long-acting basal insulin glargine 100 units/mL (iGlar), with its individual components, and the LixiLan-L trial, which compared iGlarLixi with iGlar. The GV features that were measured were mean and SD of self-measured plasma glucose (SMPG), high blood glucose index (HBGI) and low blood glucose index, area under the SMPG curve for each patient (AUCn), mean absolute glucose (MAG) and mean amplitude of glycaemic excursions (MAGE). By week 30, iGlarLixi improved all GV markers from baseline, with no increased hypoglycaemia risk. Significant improvements were observed in SMPG, SD of SMPG, HBGI, AUCn, MAG and MAGE compared with iGlar, and in SMPG, HBGI and AUCn, compared with Lixi.
For the full article, click HERE.
